期刊文献+

慢病毒介导的RNA干扰技术构建hOGG1和hMTH1基因缺陷细胞模型

Construction of hOGG1 and hMTH1 gene-deficient cell model by lentivirus-mediated RNA interference
下载PDF
导出
摘要 目的:分别建立8-羟基鸟嘌呤糖苷酶1(human 8-hydroxyguanine glycosylase,hOGG1)基因和8-羟基鸟嘌呤核苷酸酶(human Mut T homlogue,hMTH1)基因缺陷细胞模型,为进一步研究两个基因的相互关系提供理想的研究平台。方法:利用慢病毒载体介导的小发夹状RNA(small hairpin RNA,shRNA)转入人胚胎肾细胞(293FT)包装慢病毒,用所得到的慢病毒感染人胚肺成纤维细胞(HFL),杀稻瘟菌素筛选稳定表达的细胞株,荧光显微镜下观察慢病毒的包装效率和感染效率,Real-time RT-PCR鉴定基因干扰效果。结果:得到了滴度较高的慢病毒,感染靶细胞后得到hOGG1基因和hMTH1基因缺陷细胞模型,hOGG1 mRNA和hMTH1mRNA表达水平分别比正常HFL细胞下降了90%和60%。结论:通过慢病毒包装技术,成功构建hOGG1基因和hMTH1基因缺陷细胞模型。 OBJECTIVE:In order to establish an ideal research platform to make further study of the relationship between the two genes,hOGG1 and hMTH1,two cell models with gene defect were established. METHODS:The lentivirus vector with shRNA targeting human 8-oxoguanine DNA glycosylase 1(hOGG1) mRNA and 8-oxoguanine nucleoside triphosphatase 1(hMTH1) mRNA were transfected into 293FT cells by liposome.Then the lentivirus supernatant was obtained and used for infecting human embryonic lung fibroblasts(HFL).The defective cells were selected with blasticidin,and fluorescence microscope was used as a tool for observing the packaging efficiency and infection efficiency.The efficacy of gene knockout was tested by Real-time RT PCR.RESULTS:The lentivirus with high titer were obtained and the hOGG1- deficient and the hMTH1-deficient HFL cell strains were obtained after blasticidin selection.The level of hOGG1 and hMTH1 mRNA expression were decreased,90%and 60%,respectively. CONCLUSION:Lentivirus packaging technology could be mastered skillfully.hOGG 1-deficient and hMTH1-deficient HFL cell models were successfully established.
出处 《癌变.畸变.突变》 CAS CSCD 2011年第1期4-8,共5页 Carcinogenesis,Teratogenesis & Mutagenesis
基金 国家自然科学基金(30872149/C1504 81072323/H2607) 广东省自然科学基金项目(8451802003000336)
关键词 慢病毒 RNA干扰 HOGG1 hMTH1 lentivirus RNAi hOGG1 hMTH1
  • 相关文献

参考文献1

二级参考文献16

  • 1Rowan S, Ludwig RL, Haupt Y, et al. Specific loss of apoptotic but not cell-cycle arrest function in a human turnout derived p53 mutant [J]. EMBO, 1996, 15(4): 827 -838.
  • 2http://www-p53.iarc.fr/.
  • 3Samuels-Lev Y, O'Connor D J, Bergamaschi D, et al. ASPP proteins specifically stimulate the apoptotic function of p53 [J].Mol Cell, 2001, 8(4):781-794.
  • 4Sullivan A, Lu X. ASPP: a new family of oncogenes and tumour suppressor genes [J].Br J Cancer, 2007, 96(2):196-200.
  • 5Liu Z J, Lu X, Zhong S, et al. ASPP--Apoptotic specific regulator of p53 [J]. Biochim Biophys Acta, 2005, 1756(1):77-80.
  • 6Slee EA, Lu X. The ASPP family: deciding between life and death after DNA damage [J]. Toxicol Lett, 2003, 139(2-3):81-87.
  • 7Vives V, Slee EA, Lu X. ASPP2: a gene that controls life and death in vivo [J]. Cell Cycle, 2006, 5(19):2187-2190.
  • 8Bergamaschi D, Samuels Y, Jin B, et al. ASPP1 and ASPP2: common activators of p53 family members [J]. Mol Cell 8iol, 2004, 24(3):1341-1350.
  • 9Bergamaschi D, Samuels Y, O'Neil N J, et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human [J]. Nat Genet, 2003, 33(2):162-1671.
  • 10Bergamaschi D, Samuels Y, Sullivan A, et al. iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53 [J]. Nat Genet, 2006,38 (10):1133- 1141.

共引文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部